On October 1, 2026, Coinbase completed the migration of its international exchange operations to Deribit. This transition means that the previous Coinbase international trading platform is now in read-only mode, effectively ending active trading there. Institutional clients affected by this change must now use Deribit for their international trading activities. This move aims to streamline Coinbase's services and possibly leverage Deribit's specialized infrastructure for international markets.
The migration of Coinbase's international exchange to Deribit is the story's subject, with Pluang market data providing context. As of Oct 05, 2026 18:02 WIB, 35 of 50 major cryptocurrencies on Pluang rose while 14 fell. Notable price changes include Dogecoin at Rp1.725 with a 3.54% increase, Filecoin at Rp19.700 up 3.11%, and Axie Infinity at Rp23.711 down 4.00%.
Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. ...
Tyson Foods is experiencing significant losses in its beef segment, with a projected loss of $500 million to $650 million for the fiscal year, causing its stock to decline. However, the company's dividend remains secure because its chicken and prepar...
Amazon is investing hundreds of billions in data centers, servers, and chips, aiming for long-term returns as these assets generate revenue over decades. AWS revenue grew 37% in Q2 with a strong operating margin, and the company has a $496 billion ba...
Northern Graphite Corporation has engaged German advisory firm DGWA to enhance its investor relations and visibility in Europe, especially in German-speaking regions. The partnership aims to attract strategic investors, institutional funds, and indus...
TuHURA Biosciences announced the issuance of a U.S. patent for their Delta Opioid Receptor (DOR) antagonist technology, which reprograms immunosuppressive cells to enhance cancer immunotherapy. This patent covers the use of DOR antagonists in combina...
